Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
47
ARKG Quote, Financials, Valuation and Earnings
Last price:
$21.13
Seasonality move
:
11.26%
Day range:
$21.09 - $22.28
52-week range:
$17.51 - $31.16
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.2M
Avg. volume:
3.1M
1-year change:
-15.78%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
$21.13 | -- | -- | -- | $0.00 | 0% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$53.82 | -- | -- | -- | $0.00 | 0% | -- |
|
IHF
iShares US Healthcare Providers ETF
|
$49.67 | -- | -- | -- | $0.11 | 0.83% | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
$36.34 | -- | -- | -- | $0.03 | 0.07% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$76.39 | -- | -- | -- | $0.01 | 0.18% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | 2.860 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.267 | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | 1.251 | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | 1.485 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.543 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARKG
ARK Genomic Revolution ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
IHF
iShares US Healthcare Providers ETF
|
-- | -- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
ARK Genomic Revolution ETF vs. Competitors
-
Which has Higher Returns ARKG or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About ARKG or BBP?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is ARKG or BBP More Risky?
ARK Genomic Revolution ETF has a beta of 1.801, which suggesting that the stock is 80.097% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.994%.
-
Which is a Better Dividend Stock ARKG or BBP?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or BBP?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns ARKG or IHF?
iShares US Healthcare Providers ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat iShares US Healthcare Providers ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- IHFiShares US Healthcare Providers ETF-- -- -- -
What do Analysts Say About ARKG or IHF?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Healthcare Providers ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than iShares US Healthcare Providers ETF, analysts believe ARK Genomic Revolution ETF is more attractive than iShares US Healthcare Providers ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 IHFiShares US Healthcare Providers ETF0 0 0 -
Is ARKG or IHF More Risky?
ARK Genomic Revolution ETF has a beta of 1.801, which suggesting that the stock is 80.097% more volatile than S&P 500. In comparison iShares US Healthcare Providers ETF has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.318%.
-
Which is a Better Dividend Stock ARKG or IHF?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iShares US Healthcare Providers ETF offers a yield of 0.83% to investors and pays a quarterly dividend of $0.11 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. iShares US Healthcare Providers ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or IHF?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than iShares US Healthcare Providers ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than iShares US Healthcare Providers ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while iShares US Healthcare Providers ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for iShares US Healthcare Providers ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- IHFiShares US Healthcare Providers ETF-- -- -- --
-
Which has Higher Returns ARKG or PTH?
Invesco Dorsey Wright Healthcare Momentum ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat Invesco Dorsey Wright Healthcare Momentum ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- -
What do Analysts Say About ARKG or PTH?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Dorsey Wright Healthcare Momentum ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than Invesco Dorsey Wright Healthcare Momentum ETF, analysts believe ARK Genomic Revolution ETF is more attractive than Invesco Dorsey Wright Healthcare Momentum ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 PTHInvesco Dorsey Wright Healthcare Momentum ETF0 0 0 -
Is ARKG or PTH More Risky?
ARK Genomic Revolution ETF has a beta of 1.801, which suggesting that the stock is 80.097% more volatile than S&P 500. In comparison Invesco Dorsey Wright Healthcare Momentum ETF has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.464%.
-
Which is a Better Dividend Stock ARKG or PTH?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Dorsey Wright Healthcare Momentum ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. Invesco Dorsey Wright Healthcare Momentum ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or PTH?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than Invesco Dorsey Wright Healthcare Momentum ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than Invesco Dorsey Wright Healthcare Momentum ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while Invesco Dorsey Wright Healthcare Momentum ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for Invesco Dorsey Wright Healthcare Momentum ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- --
-
Which has Higher Returns ARKG or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to ARK Genomic Revolution ETF's net margin of --. ARK Genomic Revolution ETF's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ARKGARK Genomic Revolution ETF-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About ARKG or XBI?
ARK Genomic Revolution ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that ARK Genomic Revolution ETF has higher upside potential than SPDR S&P Biotech ETF, analysts believe ARK Genomic Revolution ETF is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings ARKGARK Genomic Revolution ETF0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is ARKG or XBI More Risky?
ARK Genomic Revolution ETF has a beta of 1.801, which suggesting that the stock is 80.097% more volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.396%.
-
Which is a Better Dividend Stock ARKG or XBI?
ARK Genomic Revolution ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SPDR S&P Biotech ETF offers a yield of 0.18% to investors and pays a quarterly dividend of $0.01 per share. ARK Genomic Revolution ETF pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARKG or XBI?
ARK Genomic Revolution ETF quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. ARK Genomic Revolution ETF's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, ARK Genomic Revolution ETF's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ARK Genomic Revolution ETF is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARKGARK Genomic Revolution ETF-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
